<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38937" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antiepileptic Drug Monitoring</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Selim</surname>
            <given-names>Mohammad</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anilkumar</surname>
            <given-names>Arayamparambil C.</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cichowski</surname>
            <given-names>Erica</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammad Selim declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arayamparambil Anilkumar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Erica Cichowski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38937.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Antiepileptic drug-level monitoring has been a standard practice in managing seizures since the introduction of antiepileptic drugs or antiseizure medications. Conforming antiepileptic drug levels to predefined therapeutic margins proves elusive, as clinicians often inflate these values. This&#x000a0;activity discusses the effectiveness, diversity, and relevance of monitoring antiepileptic drug levels across various clinical milieus.</p>
        <p>The diagnosis of epilepsy primarily hinges on clinical evaluation, supported by adjunctive investigative modalities such as electroencephalogram&#x000a0;and magnetic resonance imaging. Similarly, gauging antiepileptic drug efficacy relies on clinical appraisal, with antiepileptic drug levels as supplementary information in specific scenarios. A comprehensive understanding of evolving guidelines and research, coupled with adept critical analysis skills, are vital for deciphering antiepileptic drug levels within the context of individual patient presentations and treatment objectives. Furthermore, fostering a patient-centered approach mandates accounting for distinctive patient characteristics and preferences, coupled with effective communication regarding treatment regimens and the rationale behind antiepileptic drug monitoring. Equipping healthcare professionals with in-depth knowledge of antiepileptic drug monitoring protocols empowers them to actively engage in shared decision-making with patients, ultimately fostering superior treatment outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate the&#x000a0;misconception surrounding the practice of maintaining antiepileptic drugs within laboratory-defined therapeutic ranges.</p></list-item><list-item><p>Identify&#x000a0;the efficacy, variability, and utility of monitoring antiepileptic drug levels in various settings.</p></list-item><list-item><p>Assess&#x000a0;the clinical assessment of antiepileptic drug efficacy.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes for patients who might benefit from&#x000a0;antiepileptic drug monitoring.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38937&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38937">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38937.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Antiepileptic drug-level monitoring has been a common clinical practice since the advent of antiepileptic drugs or antiseizure medications.<xref ref-type="bibr" rid="article-38937.r1">[1]</xref>&#x000a0;Maintaining antiepileptic drugs within laboratory-defined therapeutic ranges is a&#x000a0;myth, with professionals overestimating values in most clinical settings. Epilepsy is primarily diagnosed through clinical evaluation, with diagnostic modalities such as electroencephalogram&#x000a0;and&#x000a0;magnetic resonance imaging considered complementary investigations.<xref ref-type="bibr" rid="article-38937.r2">[2]</xref>&#x000a0;The assessment of antiepileptic drug efficacy&#x000a0;should also be clinical, and the antiepileptic drug level should be utilized as a complementary tool in selected situations.</p>
      </sec>
      <sec id="article-38937.s3" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Patient-Specific Antiepileptic Drug Levels</bold>
</p>
        <p>A&#x000a0;single antiepileptic drug level can reasonably be assessed while the patient is seizure-free, serving as a benchmark for future reference if seizure control deteriorates or symptoms suggestive of toxicity develop.<xref ref-type="bibr" rid="article-38937.r3">[3]</xref>&#x000a0;Regular monitoring of valproic acid levels is crucial in cases of toxicity, with intervals typically set every 2 to 4 hours until a decrease in serum valproate levels is observed.<xref ref-type="bibr" rid="article-38937.r4">[4]</xref></p>
        <p>
<bold>Breakthrough Seizures</bold>
</p>
        <p>In cases of patients with epilepsy who&#x000a0;have remained stable over a period and present with unprovoked breakthrough seizures, assessing drug levels may provide valuable guidance for treatment decisions.<xref ref-type="bibr" rid="article-38937.r5">[5]</xref></p>
        <p>
<bold>Status Epilepticus</bold>
</p>
        <p>In managing status epilepticus, the primary goal is to abort the attack using a benzodiazepine followed by an antiepileptic drug load, often with phenytoin. Monitoring antiepileptic drug levels in this setting could guide further loading if clinically indicated.<xref ref-type="bibr" rid="article-38937.r5">[5]</xref></p>
        <p>
<bold>Drug Substitution</bold>
</p>
        <p>Variations exist between different generic and brand-name antiepileptic drugs. Therefore, guidelines recommend against switching between different generics and brands. However, monitoring antiepileptic drug levels can aid in dose adjustments when substitution is necessary.<xref ref-type="bibr" rid="article-38937.r6">[6]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The efficacy of antiepileptic drugs can be influenced by factors such as pregnancy, liver disease, renal diseases, drug interactions in polypharmacy, and aging. Therefore, drug levels can assist in dose adjustments to achieve a seizure-free quality of life.<xref ref-type="bibr" rid="article-38937.r3">[3]</xref></p>
      </sec>
      <sec id="article-38937.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Variability in Antiseizure Medication Levels</bold>
</p>
        <p>Multiple clinical studies have been conducted to test the efficacy of monitoring antiepileptic drug levels in various clinical settings. One such study involved 114 inpatients in the United Kingdom. The medications studied included phenytoin, valproate, carbamazepine, lamotrigine, and phenobarbitone. To a lesser extent, other levels had been ordered, such as benzodiazepines, topiramate, gabapentin, and vigabatrin. The findings of the study indicated that antiepileptic drug levels proved beneficial with phenytoin, carbamazepine, and phenobarbitone. Lamotrigine has different therapeutic&#x000a0;ranges, making interpretation of the levels difficult and leading to inappropriate dosage adjustments.<xref ref-type="bibr" rid="article-38937.r7">[7]</xref>&#x000a0;Valproate has a short half-life, making its measurement low-yield and primarily reflective of short-term compliance.</p>
        <p>Conversely, phenytoin has a long half-life; hence, the antiepileptic drug level reflects long-term usage. The newer antiepileptic drugs have broader indications and are safer compared to the older ones. However, some of these newer agents lack generalizable reference ranges. For these reasons, level monitoring with newer agents is not useful.<xref ref-type="bibr" rid="article-38937.r8">[8]</xref>&#x000a0;Furthermore, variability in antiepileptic drug levels exists within patient populations and between clinical settings and is often based on the type and severity of the seizure.<xref ref-type="bibr" rid="article-38937.r9">[9]</xref>&#x000a0;</p>
        <p>A study demonstrated that antiepileptic drug levels vary considerably among patients treated for idiopathic generalized tonic-clonic seizures with phenytoin. While some patients achieve a seizure-free quality of life with&#x000a0;certain antiepileptic drug levels,&#x000a0;others&#x000a0;may experience symptoms of toxicity.&#x000a0;Thus, it is impractical to generalize the efficacy of antiepileptic drug-level monitoring.<xref ref-type="bibr" rid="article-38937.r10">[10]</xref></p>
        <p>
<bold>Drug-Drug Interactions Affecting Antiseizure Medications</bold>
</p>
        <p>Clinicians should be aware of the pharmacokinetics of medications, particularly in cases of polypharmacy. Medications&#x000a0;utilizing metabolic pathways through the liver are often affected by interactions, which are commonly&#x000a0;observed in medications&#x000a0;such as valproic acid and carbamazepine. Non-seizure medications are also an important consideration, especially in hospital settings. Carbapenem can reduce valproic acid levels significantly and cause breakthrough seizures.<xref ref-type="bibr" rid="article-38937.r11">[11]</xref>&#x000a0;In such cases, it is important to monitor levels to guide therapy. Enzyme-inhibiting medications&#x000a0;such as valproic acid can affect the metabolism of lamotrigine, increasing the level and its half-life. Conversely, medications&#x000a0;such as estrogen-containing oral contraceptives reduce lamotrigine levels by increasing glucuronidation.<xref ref-type="bibr" rid="article-38937.r12">[12]</xref><xref ref-type="bibr" rid="article-38937.r13">[13]</xref><xref ref-type="bibr" rid="article-38937.r14">[14]</xref>&#x000a0;New-generation antiseizure medications such as gabapentin, levetiracetam, pregabalin, and vigabatrin are excreted unchanged by the kidneys and show minimal potential for drug-drug interactions.<xref ref-type="bibr" rid="article-38937.r15">[15]</xref></p>
        <p>
<bold>Clinical Monitoring Versus Drug-Level Monitoring</bold>
</p>
        <p>Multiple studies have concluded that clinical monitoring could optimally achieve seizure control. An investigation examined patients taking phenytoin and compared medication adjustments based on clinical assessment in one group to&#x000a0;adjustments based on drug level in the other group.&#x000a0;The study found that the majority of cases could be managed clinically, with only a few patients benefiting from drug-level monitoring.<xref ref-type="bibr" rid="article-38937.r16">[16]</xref>&#x000a0;This study was conducted using an old antiepileptic drug with a long half-life;&#x000a0;therefore, antiepileptic drug levels are more closely correlated with medication compliance.&#x000a0;Attempts&#x000a0;to achieve therapeutic levels in seizure-free patients with subtherapeutic levels have not shown any difference in seizure control and&#x000a0;have been associated with increased neurotoxicity.<xref ref-type="bibr" rid="article-38937.r10">[10]</xref></p>
        <p>
<bold>Antiseizure Medication Compliance</bold>
</p>
        <p>Compliance with epilepsy treatment plans is challenging due to the chronic nature of the disease, often requiring long-term pharmacologic therapy.&#x000a0;Non-compliance manifests in various forms, with erratic non-compliance, characterized by inconsistent dosing, being the most prevalent.&#x000a0;This inconsistency results in unreliable therapeutic antiepileptic drug levels and variability in seizure control.<xref ref-type="bibr" rid="article-38937.r17">[17]</xref>&#x000a0;Some patients exhibit white coat adherence, wherein they take their medications&#x000a0;1 or more days before their medical appointments, often resulting in antiepileptic drug levels within the normal ranges. In general, compliance studies are limited by their short-term nature and are difficult to correlate with actual behavior, which is known to vary over long periods in chronic conditions such as epilepsy.<xref ref-type="bibr" rid="article-38937.r18">[18]</xref>&#x000a0;</p>
        <p>Compliance and adherence are terms used interchangeably to describe the status of not taking the medication or following the treatment plan.<xref ref-type="bibr" rid="article-38937.r19">[19]</xref>&#x000a0;Compliance implies a paternalistic approach and fails to consider the patient's perspective. Adherence reflects the patient's role and perspective in the treatment plan. Compliance&#x000a0;or adherence to a treatment plan is a complex process stemming from the strength of the relationships between physicians, patients, and the healthcare system. Compliance is paternalistic, passive, and episodic. Conversely, adherence is collaborative, active, and continuous. Therefore, many clinicians prefer to use the term adherence over compliance to position the patient at the center of their treatment plan and emphasize a holistic approach to achieving positive long-term outcomes when treating complex chronic conditions such as epilepsy.<xref ref-type="bibr" rid="article-38937.r20">[20]</xref></p>
        <p>
<bold>Other Ways to Promote Antiepileptic Drug-Level Monitoring</bold>
</p>
        <p>To effectively guide patients in managing their medications, clinicians must investigate the reasons for non-adherence and assist patients in overcoming them. However, it depends on the patient's ability to adhere to their medications eventually. Various methods can be employed to assess compliance, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient reporting, which depends on the patient recalling, their reliability as a historian, and the pattern of compliance with other medications</p>
          </list-item>
          <list-item>
            <p>Monitoring drug levels, which has traditionally been used as the only reliable way to monitor adherence by most clinicians</p>
          </list-item>
          <list-item>
            <p>Utilization of diaries&#x000a0;<xref ref-type="bibr" rid="article-38937.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Direct observation of medication administration</p>
          </list-item>
          <list-item>
            <p>Pill counts</p>
          </list-item>
          <list-item>
            <p>Implementation of behavioral interventions and intensive reminders&#x000a0;<xref ref-type="bibr" rid="article-38937.r22">[22]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>There are many effective ways to help patients adhere to their medication other than monitoring drug levels. However, relying solely on drug level monitoring presents challenges, as it can be expensive, unreliable, and, in some cases, lead to unnecessary dosage adjustments, potentially increasing the risk of&#x000a0;adverse effects.</p>
      </sec>
      <sec id="article-38937.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Achieving optimal outcomes in the treatment of epilepsy rarely requires monitoring of antiepileptic drug levels.<xref ref-type="bibr" rid="article-38937.r23">[23]</xref>&#x000a0;Although this has been a common clinical practice for years, newer antiepileptic drugs and more recent evidence suggest that the value of antiepileptic drug-level monitoring is low except for the few scenarios mentioned above. Clinical monitoring within the broader context of a supportive, patient-centered treatment plan based on a therapeutic physician-patient relationship is the key to success.</p>
        <list list-type="bullet">
          <list-item>
            <p>Although levetiracetam and&#x000a0;brivaracetam levels are not routinely monitored, it is important to note that they may be altered during the first trimester.<xref ref-type="bibr" rid="article-38937.r24">[24]</xref>&#x000a0;Monitoring of levetiracetam serum levels is important during pregnancy.<xref ref-type="bibr" rid="article-38937.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Due to its complex pharmacokinetics, adjusting phenytoin dosage accurately in critically ill patients with low albumin levels is challenging. The commonly used Sheiner-Tozer equation often fails to predict free phenytoin concentration accurately, potentially leading to inappropriate dosing.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>To address this, the corrected phenytoin level can be calculated using the formula: Corrected phenytoin =&#x000a0;obtained phenytoin level/([adjustment x albumin] + 0.1). Here, adjustment= 0.275; if creatine clearance is &#x0003c;20 mL/min, adjustment= 0.2.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>This study compared the Sheiner-Tozer equation with direct measurement of free phenytoin concentration using high-performance liquid chromatography in such patients, revealing discrepancies between the&#x000a0;2 methods. Direct measurement of free phenytoin concentration is recommended for individualizing phenytoin dosage in critically ill patients with low albumin levels.<xref ref-type="bibr" rid="article-38937.r26">[26]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38937.s6" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>In the current environment of patients seeking healthy foods and herbal and non-proprietary medications, therapeutic drug monitoring can pose challenges. A comprehensive understanding of the patient's medication regimen is essential to consider potential drug-drug interactions and minimize undesired changes in antiepileptic drug levels. The recent increase in the use of cannabidiol as an antiepileptic drug has heightened the need for frequent monitoring of certain medications,&#x000a0;such as clobazam, during concomitant therapy.<xref ref-type="bibr" rid="article-38937.r27">[27]</xref>&#x000a0;In combination with valproate&#x000a0;or clobazam, cannabidiol&#x000a0;can&#x000a0;cause increased liver enzymes, notably alanine aminotransferase and aspartate aminotransferase;&#x000a0;therefore,&#x000a0;patients receiving this combination may benefit from additional liver enzyme monitoring. Animal studies have shown cannabidiol&#x000a0;to increase clobazam anticonvulsant activity&#x000a0;through CYP3A4 activity, but only when an anticonvulsant dose of cannabidiol&#x000a0;was used. Despite increased serum clobazam concentrations, administering sub-therapeutic doses of cannabidiol did not result in heightened anticonvulsant effects.<xref ref-type="bibr" rid="article-38937.r23">[23]</xref><xref ref-type="bibr" rid="article-38937.r28">[28]</xref><xref ref-type="bibr" rid="article-38937.r29">[29]</xref></p>
        <p>
<bold>Trough Versus Free levels</bold>
</p>
        <p>Trough levels and free levels of antiepileptic drugs are crucial parameters for therapeutic drug monitoring in patients with epilepsy. Trough levels represent the concentration of antiepileptic drugs in the blood at the lowest point, typically just before the next dose is due. This consideration is especially important in antiepileptic drugs with short half-lives. These levels are significant as they indicate the minimum concentration of the drug between doses, ensuring that therapeutic levels are maintained throughout the dosing interval. For antiepileptic drugs, maintaining adequate trough levels is essential for preventing breakthrough seizures and optimizing therapeutic efficacy.</p>
        <p>On the other hand, free levels denote the concentration of the unbound, pharmacologically active fraction of the drug in the bloodstream. Measuring free levels becomes crucial when protein binding may be altered, such as during severe&#x000a0;systemic illness&#x000a0;or drug interactions. When protein binding is altered, it can influence&#x000a0;the availability of the active form of the drug, potentially leading to inaccurate assessments of therapeutic efficacy based on total drug concentrations alone. Considerable variability exists in the free fraction of phenytoin, carbamazepine, and valproic acid among individuals, particularly when influenced by concurrent disease or drug interactions. Alterations in binding can render total concentrations unreliable indicators of pharmacologically active drug levels in plasma, potentially leading clinicians to make inappropriate dosage adjustments. Prioritizing the measurement of free drug concentration can mitigate interpretative errors and may be the preferred method for monitoring therapy in specific patient populations.<xref ref-type="bibr" rid="article-38937.r30">[30]</xref><xref ref-type="bibr" rid="article-38937.r31">[31]</xref><xref ref-type="bibr" rid="article-38937.r32">[32]</xref></p>
      </sec>
      <sec id="article-38937.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Nurse practitioners, internists, primary care providers, neurologists,&#x000a0;or emergency department physicians frequently encounter patients undergoing treatment with antiepileptic drugs. In the past, it was widely believed that routine drug monitoring of antiepileptics was beneficial, but except for a few cases, this&#x000a0;practice is no longer recommended. Instead,&#x000a0;clinical monitoring within the context of a supportive, patient-centered, interprofessional team treatment plan based on a therapeutic clinician-patient relationship with the support of nurses and pharmacists is the key to success.&#x000a0;A systematic&#x000a0;review emphasizes that not every antiepileptic drug requires therapeutic drug monitoring.&#x000a0;Therapeutic drug monitoring can enhance clinical care, particularly for antiepileptic drugs&#x000a0;such as phenytoin with complex pharmacokinetics, but its requirement differs based on the drug and individual patient factors.<xref ref-type="bibr" rid="article-38937.r33">[33]</xref></p>
        <p>This interprofessional team includes physicians, neurologists, nurse practitioners, physician assistants,&#x000a0;nurses, and pharmacists. In addition to verifying appropriate dosing and performing medication reconciliation, pharmacists should emphasize the importance of medication compliance to patients and the need for close follow-up. If there is evidence of non-compliance, pharmacists should discuss the situation with clinicians managing the case. Pharmacists and nurses should assist in educating patients about the adverse effects of the drugs so that they know when to report back to clinicians; they must also be alert to signs of therapeutic failure, which must be documented and reported to other team members as necessary so that regimen modification can be implemented if required. Only through such an interprofessional team approach with open communication channels between all team members can the morbidity of anticonvulsants be reduced and safe outcomes be achieved.</p>
      </sec>
      <sec id="article-38937.s8" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Nurses responsible for administering antiepileptic drugs should independently verify the dose and route of administration. They should also understand the potential adverse effects of the drugs and educate patients to enhance safety measures. If a dose does not appear reasonable, the nurse should contact the prescribing clinician immediately.</p>
      </sec>
      <sec id="article-38937.s9" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>Several anticonvulsants have the potential to cause adverse cardiac effects when administered intravenously.<xref ref-type="bibr" rid="article-38937.r34">[34]</xref> Thus, patients should be placed on a cardiac monitor, and their vital signs should be measured frequently. Any&#x000a0;adverse effects should be immediately reported to the prescriber.</p>
      </sec>
      <sec id="article-38937.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38937&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38937">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38937/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38937">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38937.s11">
        <title>References</title>
        <ref id="article-38937.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>French</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines.</article-title>
            <source>Epilepsy Curr</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>69</fpage>
            <page-range>69-72</page-range>
            <pub-id pub-id-type="pmid">32077329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benbadis</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Beniczky</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bertram</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>MacIver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mosh&#x000e9;</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>The role of EEG in patients with suspected epilepsy.</article-title>
            <source>Epileptic Disord</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-155</page-range>
            <pub-id pub-id-type="pmid">32364504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St Louis</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>Monitoring antiepileptic drugs: a level-headed approach.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-9</page-range>
            <pub-id pub-id-type="pmid">19949569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Nagalli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Valproate Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">32809733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stepanova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Beran</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy.</article-title>
            <source>Epilepsy Behav</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>42</volume>
            <fpage>7</fpage>
            <page-range>7-9</page-range>
            <pub-id pub-id-type="pmid">25499154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atif</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Azeem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarwar</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature.</article-title>
            <source>Springerplus</source>
            <year>2016</year>
            <volume>5</volume>
            <fpage>182</fpage>
            <pub-id pub-id-type="pmid">27026878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walters</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hutchings</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Inappropriate requests for serum anti-epileptic drug levels in hospital practice.</article-title>
            <source>QJM</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>6</issue>
            <fpage>337</fpage>
            <page-range>337-41</page-range>
            <pub-id pub-id-type="pmid">15152107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krasowski</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2010</year>
            <month>Jun</month>
            <day>11</day>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>1909</fpage>
            <page-range>1909-1935</page-range>
            <pub-id pub-id-type="pmid">20640233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haenel</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type.</article-title>
            <source>Neurology</source>
            <year>1984</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>1252</fpage>
            <page-range>1252-5</page-range>
            <pub-id pub-id-type="pmid">6540414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study.</article-title>
            <source>Epilepsia</source>
            <year>1988</year>
            <season>Mar-Apr</season>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-39</page-range>
            <pub-id pub-id-type="pmid">3280304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fratoni</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Colmerauer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Linder</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Nicolau</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Kuti</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>A Retrospective Case Series of Concomitant Carbapenem and Valproic Acid Use: Are Best Practice Advisories Working?</article-title>
            <source>J Pharm Pract</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>537</fpage>
            <page-range>537-541</page-range>
            <pub-id pub-id-type="pmid">34958247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kalia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lamotrigine Drug Interactions: Ignorance is not Bliss.</article-title>
            <source>Kans J Med</source>
            <year>2022</year>
            <volume>15</volume>
            <fpage>109</fpage>
            <page-range>109-111</page-range>
            <pub-id pub-id-type="pmid">35345572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mostacci</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Esposto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bisulli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Licchetta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tinuper</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Estrogen-related seizure exacerbation following hormone therapy for assisted reproduction in women with epilepsy.</article-title>
            <source>Seizure</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>61</volume>
            <fpage>200</fpage>
            <page-range>200-202</page-range>
            <pub-id pub-id-type="pmid">30199820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bachman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Macken</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gerard</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Contraceptive vaginal ring reduces lamotrigine levels.</article-title>
            <source>Epilepsy Behav</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>111</volume>
            <fpage>107162</fpage>
            <pub-id pub-id-type="pmid">32575009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunasekera</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Sirven</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Feyissa</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence -assisted antiseizure medication selection ready for prime time?</article-title>
            <source>J Cent Nerv Syst Dis</source>
            <year>2023</year>
            <volume>15</volume>
            <fpage>11795735231209209</fpage>
            <pub-id pub-id-type="pmid">37868934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jannuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cian</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fattore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gatti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bartoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monaco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy.</article-title>
            <source>Epilepsia</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>222</fpage>
            <page-range>222-30</page-range>
            <pub-id pub-id-type="pmid">10691121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherwin</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Robb</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lechter</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Improved control of epilepsy by monitoring plasma ethosuximide.</article-title>
            <source>Arch Neurol</source>
            <year>1973</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>178</fpage>
            <page-range>178-81</page-range>
            <pub-id pub-id-type="pmid">4631034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eatock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Managing patient adherence and quality of life in epilepsy.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-31</page-range>
            <pub-id pub-id-type="pmid">19300542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraser</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Concordance, compliance, preference or adherence.</article-title>
            <source>Patient Prefer Adherence</source>
            <year>2010</year>
            <volume>4</volume>
            <fpage>95</fpage>
            <page-range>95-6</page-range>
            <pub-id pub-id-type="pmid">22090796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aronson</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Compliance, concordance, adherence.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>383</fpage>
            <page-range>383-4</page-range>
            <pub-id pub-id-type="pmid">17378797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fisher</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Tracking epilepsy with an electronic diary.</article-title>
            <source>Acta Paediatr</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>99</volume>
            <issue>4</issue>
            <fpage>516</fpage>
            <page-range>516-8</page-range>
            <pub-id pub-id-type="pmid">20105139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Aqeel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gershuni</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Al-Sabhan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hiligsmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Oct</month>
            <day>22</day>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>CD008312</fpage>
            <pub-id pub-id-type="pmid">33089492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000e1;zquez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guevara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guido</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Schaiquevich</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain.</article-title>
            <source>Biomed Res Int</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>3902740</fpage>
            <pub-id pub-id-type="pmid">32855964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hahn</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Menzler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Poeplau</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Knake</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature.</article-title>
            <source>Neurol Res Pract</source>
            <year>2024</year>
            <month>Mar</month>
            <day>21</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <pub-id pub-id-type="pmid">38509597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barchel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gandelman-Marton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brandriss</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blatt</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ziv-Baran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Neufeld</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Dinavitser</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kohn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shaniv</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De-Haan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ofek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stepensky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Berkovitch</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic levetiracetam monitoring during pregnancy: "mind the gap".</article-title>
            <source>Ther Adv Chronic Dis</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>2040622319851652</fpage>
            <pub-id pub-id-type="pmid">31191874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilfred</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chacko</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prabha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Estimation of Free Phenytoin Concentration in Critically Ill Patients with Hypoalbuminemia: Direct-measurement vs Traditional Equations.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>682</fpage>
            <page-range>682-687</page-range>
            <pub-id pub-id-type="pmid">35836626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilmartin</surname>
                <given-names>CGS</given-names>
              </name>
              <name>
                <surname>Dowd</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>APJ</given-names>
              </name>
              <name>
                <surname>Harijan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Interaction of cannabidiol with other antiseizure medications: A narrative review.</article-title>
            <source>Seizure</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>86</volume>
            <fpage>189</fpage>
            <page-range>189-196</page-range>
            <pub-id pub-id-type="pmid">33541771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Absalom</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Abelev</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Doohan</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Chebib</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGregor</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.</article-title>
            <source>Epilepsia</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>60</volume>
            <issue>11</issue>
            <fpage>2224</fpage>
            <page-range>2224-2234</page-range>
            <pub-id pub-id-type="pmid">31625159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.</article-title>
            <source>Drugs</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>79</volume>
            <issue>13</issue>
            <fpage>1435</fpage>
            <page-range>1435-1454</page-range>
            <pub-id pub-id-type="pmid">31372958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tobler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000f6;sli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000fc;hlebach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Free phenytoin assessment in patients: measured versus calculated blood serum levels.</article-title>
            <source>Int J Clin Pharm</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>303</fpage>
            <page-range>303-9</page-range>
            <pub-id pub-id-type="pmid">26746902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Boyert</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mitro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McShane</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Development and Validation of a Free Carbamazepine Assay on an Automated Chemistry Analyzer.</article-title>
            <source>J Appl Lab Med</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>357</fpage>
            <page-range>357-362</page-range>
            <pub-id pub-id-type="pmid">32445379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>VFS</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dahri</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetic Monitoring of Free Valproic Acid Levels: A Systematic Review.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>61</volume>
            <issue>10</issue>
            <fpage>1345</fpage>
            <page-range>1345-1363</page-range>
            <pub-id pub-id-type="pmid">36040614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Roubaie</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Guadagno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramanakumar</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AQ</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Clinical utility of therapeutic drug monitoring of antiepileptic drugs: Systematic review.</article-title>
            <source>Neurol Clin Pract</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>344</fpage>
            <page-range>344-355</page-range>
            <pub-id pub-id-type="pmid">32983615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38937.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sivathamboo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Minato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Casillas-Espinosa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Todaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seneviratne</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Yerra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nicolo</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Perucca</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sparks</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Serious Cardiac Arrhythmias Detected by Subcutaneous Long-term Cardiac Monitors in Patients With Drug-Resistant Epilepsy.</article-title>
            <source>Neurology</source>
            <year>2022</year>
            <month>May</month>
            <day>10</day>
            <volume>98</volume>
            <issue>19</issue>
            <fpage>e1923</fpage>
            <page-range>e1923-e1932</page-range>
            <pub-id pub-id-type="pmid">35387849</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
